

Improvement of Plasma Biomarkers after Switching Stroke Patients from Other ARBs to Olmesartan.

Tada Y, et al. J Stroke Cerebrovasc Dis. 2015; 24(7): 1487-92.

- Managing hypertension is crucial for preventing stroke recurrence. Some patients with stroke experience resistant hypertension.
- It was observed that after switching patients with stroke or silent cerebral infarction from other ARBs to olmesartan, their plasma level of biomarkers which conferred protection against vascular damage [e.g., Ang-(1-7)] and metabolic syndrome (e.g., adiponectin) increased.
- Markers of oxidative stress were lower than baseline.
- The patients attained their BP goal; No adverse events occurred.

Switching from other ARBs to olmesartan may be a promising therapeutic option in patients with resistant hypertension.